Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
ApexOnco Front Page
Recent articles
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
The company secures funding to push its lead candidate towards US approval.
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
ELVN-001 is made to look more like Terns’ TERN-701.
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
JP Morgan approaches.
